1. CDN–treated MOC1 tumors demonstrate enhanced activation of innate and antigen-specific adaptive immunity.
CDN–treated MOC1 tumors demonstrate enhanced activation of innate and antigen-specific adaptive immunity. Tumors and tumor DLN from control and R,R-CDG–treated MOC1 tumor–bearing mice were harvested and analyzed by flow cytometry and immunofluorescence 48 hours after the last R,R-CDG treatment. A, Quantification of PD-L1 and H2-Kb expression on live CD45.2−CD31− tumor cells or PD-L1 expression on live CD45.2+CD31−-infiltrating immune cells from tumors following intratumoral R,R-CDG treatment (n = 5 mice/group). B, Representative H&E (top two panels) and immunofluorescence analysis (bottom) of PD-L1 (red) with DAPI counterstain (blue) in control and R,R-CDG–treated tumors. Magnification, 40×. C, Quantification of DLN total and CD8+ DCs (left) and expression of DC activation markers (right) following intratumoral R,R-CDG treatment of MOC1 tumors. #, P < 0.01 for all markers. D, Quantification of total CD8+ TILs with activation markers (left), and quantification of p15E604–611 antigen–specific CD8+ TILs (tetramer positive) and CD107a (right) following intratumoral R,R-CDG treatment of MOC1 tumors. Data presented as absolute number of cells per 104 live cells collected. #, P < 0.01 for all markers. Whole tumor (E) and DLN (F) tissues were analyzed via RT-PCR for type I IFN (IFNα and IFNβ) and effector cytokine (IFNγ and TNFα) expression following R,R-CDG treatment. n = 5 mice/group. *, P < 0.05; **, P < 0.01; ***, P < 0.001, ANOVA.
Ellen Moore et al. Cancer Immunol Res 2016;4:
©2016 by American Association for Cancer Research